Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Total Current Liabilities (2022 - 2025)

Entrada Therapeutics has reported Total Current Liabilities over the past 4 years, most recently at $24.5 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $24.5 million for Q4 2025, down 38.07% from a year ago — trailing twelve months through Dec 2025 was $24.5 million (down 38.07% YoY), and the annual figure for FY2025 was $24.5 million, down 38.07%.
  • Total Current Liabilities for Q4 2025 was $24.5 million at Entrada Therapeutics, up from $24.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for TRDA hit a ceiling of $173.9 million in Q1 2024 and a floor of $15.4 million in Q1 2022.
  • Median Total Current Liabilities over the past 4 years was $32.0 million (2024), compared with a mean of $70.7 million.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 856.79% in 2023 and later plummeted 89.4% in 2025.
  • Entrada Therapeutics' Total Current Liabilities stood at $22.0 million in 2022, then skyrocketed by 622.72% to $158.8 million in 2023, then tumbled by 75.14% to $39.5 million in 2024, then crashed by 38.07% to $24.5 million in 2025.
  • The last three reported values for Total Current Liabilities were $24.5 million (Q4 2025), $24.0 million (Q3 2025), and $19.8 million (Q2 2025) per Business Quant data.